

## SCRI Trials and Trial Regimen Updates

The following updates were completed between July 19, 2024, through Aug. 22, 2024. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact [SCRI.DLEMRAlysts@scri.com](mailto:SCRI.DLEMRAlysts@scri.com).

### New Builds Completed

Study Number	Notes for New Build
24077	<p>USOR 24077 Axicabtagene Ciloleucel Day 0 + Prophylactic Dexamethasone Day 0,1,2</p> <p>USOR 24077 Bridging R-CHOP Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone D1-5 Q21D</p> <p>USOR 24077 Bridging DA-EPOCH-R Rituximab + Etoposide + Doxorubicin + Vincristine D1-4 + Cyclophosphamide D5 + Prednisone D1-5 Q21D</p> <p>USOR 24077 SOCT DA-EPOCH-R Rituximab + Etoposide + Doxorubicin + Vincristine D1-4 + Cyclophosphamide D5 + Prednisone D1-5 Q21D</p> <p>USOR 24077 SOCT R-CHOP Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone D1-5 Q21D</p>
24075	<p>USOR 24075 Trastuzumab (Herzuma) + Capecitabine D1-14 Q21D</p> <p>USOR 24075 Trastuzumab (Herzuma) + Eribulin D1,8 Q21D</p> <p>USOR 24075 Trastuzumab (Herzuma) + Gemcitabine D1,8 Q21D</p> <p>USOR 24075 Trastuzumab (Herzuma) + Vinorelbine D1,8 Q21D</p> <p>USOR 24075 Zanidatamab + Capecitabine D1-14 Q21D</p> <p>USOR 24075 Zanidatamab + Eribulin D1,8 Q21D</p> <p>USOR 24075 Zanidatamab + Gemcitabine D1,8 Q21D</p> <p>USOR 24075 Zanidatamab + Vinorelbine D1,8 Q21D</p>

Study Number	Notes for New Build
23083	USOR 23083 Maintenance Pembrolizumab Q42D USOR 23083 Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 23083 Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 23083 Volrustomig + Paclitaxel + Carboplatin Q21D USOR 23083 Volrustomig + Pemetrexed + Carboplatin Q21D
23115	USOR 23115 Volrustomig or Placebo Q21D
24030	USOR 24030 GYN 130 Phase III Doxorubicin Q21D USOR 24030 GYN 130 Phase III Paclitaxel D1,8,15 Q28D USOR 24030 GYN 130 Phase III Sacituzumab Govitecan D1,8 Q21D
23333	USOR 22333 Tucatinib (BID) + Liposomal Doxorubicin Q28D

## Updated Reference Information

Study Number	Updated Reference Information	Other Changes
21304	X	
23243	X	
22022	X	
19062	X	
22326	X	
22133	X	
21468	X	
23051	X	
23288		Dose escalation memo 1.8 to 2.7 mg

Study Number	Updated Reference Information	Other Changes
22322	X	
21304	X	
23292	X	
22106	X	
23292	X	
23212	X	
23048	X	
23016	X	
23048	X	
21365	X	
23120	X	